Open-label Adjunctive Zonisamide for Bipolar Disorder
Phase 4
Terminated
- Conditions
- Bipolar Disorders
- Registration Number
- NCT00047567
- Lead Sponsor
- Elan Pharmaceuticals
- Brief Summary
To study the safety and efficacy of zonisamide as adjunctive therapy for children and adolescents with bipolar I or II disorder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie zonisamide's efficacy in pediatric bipolar I/II disorder?
How does zonisamide compare to standard-of-care mood stabilizers in adjunctive treatment for bipolar youth?
Are there specific biomarkers that predict response to zonisamide in adolescent bipolar subtypes?
What adverse event profiles are associated with zonisamide adjunctive therapy in pediatric populations?
What are the current combination strategies involving zonisamide for treatment-resistant bipolar disorder?